A Systematic Review and Meta-analysis on the Role of Statins in the Prevention of Mortality Following Pancreatic Cancer


Citar

Texto integral

Resumo

Background: Pancreatic cancer (PC) is a type of cancer with a high incidence and case-fatality rate.

Objective: This study aimed to evaluate the role of statins in preventing mortality following PC based on scientific evidence with systematic review and meta-analysis method.

Methods: This meta-analysis considered studies published from 1980 till the end of 2022 in ISI Web of Science, Scopus, PubMed, Cochrane, Science Direct, Google Scholar, and Embase databases. Funnel diagrams and Begg's and Egger's tests were used to assess the publication bias.

Results: In general, this meta-analysis has included 19 studies (13 cohort studies, 4 case-control, and 2 randomized clinical trials (RCTs)) and a total of 100,888 patients with PC. The risk of mortality of PC in statin users in total was 0.86 (95% CI: 0.80 - 0.92, P-value (<0.001); in the case-control studies, it was equal to 0.53 (0.34-0.83); in the cohort studies, it was equal to 0.87 (0.82-0.92, P-value (<0.001); in RCTs, it was equal to 1.19 (0.99-1.42, P-value (<0.001); in studies with good quality score category, it was equal to 0.92 (0.86-0.99, P-value (<0.001), and in articles of the moderate quality score category, it was equal to 0.73 (0.64-0.84, P-value (<0.001). The results of statistical tests indicated the existence of publication bias (Begg's test (P-value = 0.002) and Egger's test (P-value = 0.004)).

Conclusion: Statins reduce the risk of mortality in patients with PC. However, no significant relation has been observed in RCTs. Therefore, it is necessary to be cautious in interpreting the results.

Sobre autores

Khatereh Anbari

Department of Community Medicine, School of Medicine, Social Determinant of Health Research Center, Lorestan University of Medical Science

Email: info@benthamscience.net

Mehdi Amiri

Department of Emergency Medicine, School of Medicine, Babol University of Medical Sciences

Email: info@benthamscience.net

Saeid Heidari-Soureshjani

Modeling in Health Research Center,, Shahrekord University of Medical Sciences

Email: info@benthamscience.net

Catherine Sherwin

Pediatric Clinical Pharmacology and Toxicology, Department of Pediatrics, Wright State University Boonshoft School of Medicine, Dayton Children's Hospital

Email: info@benthamscience.net

Karamali Kasiri

Department of Pediatrics, Shahrekord University of Medical Sciences

Autor responsável pela correspondência
Email: info@benthamscience.net

Bibliografia

  1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424. doi: 10.3322/caac.21492 PMID: 30207593
  2. Rawla, P.; Sunkara, T.; Gaduputi, V. Epidemiology of pancreatic cancer: Global trends, etiology and risk factors. World J. Oncol., 2019, 10(1), 10-27. doi: 10.14740/wjon1166 PMID: 30834048
  3. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer Statistics, 2021. CA Cancer J. Clin., 2021, 71(1), 7-33. doi: 10.3322/caac.21654 PMID: 33433946
  4. Cao, M.; Chen, W. Epidemiology of lung cancer in China. Thorac. Cancer, 2019, 10(1), 3-7. doi: 10.1111/1759-7714.12916 PMID: 30485694
  5. Mizrahi, J.D.; Surana, R.; Valle, J.W.; Shroff, R.T. Pancreatic cancer. Lancet, 2020, 395(10242), 2008-2020. doi: 10.1016/S0140-6736(20)30974-0 PMID: 32593337
  6. Longo, J.; van Leeuwen, J.E.; Elbaz, M.; Branchard, E.; Penn, L.Z. Statins as anticancer agents in the era of precision medicine. Clin. Cancer Res., 2020, 26(22), 5791-5800. doi: 10.1158/1078-0432.CCR-20-1967 PMID: 32887721
  7. Barbalata, C.I.; Tefas, L.R.; Achim, M.; Tomuta, I.; Porfire, A.S. Statins in risk-reduction and treatment of cancer. World J. Clin. Oncol., 2020, 11(8), 573-588. doi: 10.5306/wjco.v11.i8.573 PMID: 32879845
  8. Mangelinck, A.; Habel, N.; Mohr, A.; Gaspar, N.; Stefanovska, B.; Fromigué, O. Synergistic anti-tumor effect of simvastatin combined to chemotherapy in osteosarcoma. Cancers, 2021, 13(22), 5869. doi: 10.3390/cancers13225869 PMID: 34831022
  9. Mohammadian-Hafshejani, A.; Sherwin, C.M.T.; Heidari-Soureshjani, S. Do statins play any role in reducing the incidence and mortality of ovarian cancer? A systematic review and meta-analysis. J. Prev. Med. Hyg., 2020, 61(3), E331-E339. PMID: 33150223
  10. Shi, M.; Zheng, H.; Nie, B.; Gong, W.; Cui, X. Statin use and risk of liver cancer: An update meta-analysis. BMJ Open, 2014, 4(9), e005399. doi: 10.1136/bmjopen-2014-005399 PMID: 25227628
  11. Moon, D.C.; Lee, H.S.; Lee, Y.I.; Chung, M.J.; Park, J.Y.; Park, S.W.; Song, S.Y.; Chung, J.B.; Bang, S. Concomitant statin use has a favorable effect on gemcitabine-erlotinib combination chemotherapy for advanced pancreatic cancer. Yonsei Med. J., 2016, 57(5), 1124-1130. doi: 10.3349/ymj.2016.57.5.1124 PMID: 27401642
  12. Wang, Q.; Zhi, Z.; Han, H.; Zhao, Q.; Wang, X.; Cao, S.; Zhao, J. Statin use improves the prognosis of ovarian cancer: An updated and comprehensive meta analysis. Oncol. Lett., 2022, 25(2), 65. doi: 10.3892/ol.2022.13648 PMID: 36644149
  13. An, Y.; Sun, J.X.; Xu, M.Y.; Liu, C.Q.; Xu, J.Z.; Zhong, X.Y.; Hu, J.; Xia, Q.D.; Hu, H.L.; Wang, S.G. Statin use is associated with better prognosis of patients with prostate cancer after definite therapies: A systematic review and meta-analysis of cohort studies. J. Oncol., 2022, 2022, 1-10. doi: 10.1155/2022/9275466 PMID: 36425939
  14. Li, Y.; He, X.; Ding, Y.; Chen, H.; Sun, L. Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta‐analysis. Cancer Med., 2019, 8(6), 3305-3313. doi: 10.1002/cam4.2151 PMID: 31069997
  15. Nakai, Y.; Isayama, H.; Sasaki, T.; Mizuno, S.; Sasahira, N.; Kogure, H.; Kawakubo, K.; Yamamoto, N.; Hirano, K.; Ijichi, H.; Tateishi, K.; Tada, M.; Koike, K. Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: Better prognosis with statin use in diabetic patients. Pancreas, 2013, 42(2), 202-208. doi: 10.1097/MPA.0b013e31825de678 PMID: 23000889
  16. Jeon, C.Y.; Pandol, S.J.; Goodman, M.T. Survival time in pancreatic cancer patients with metabolic syndrome varies by use of insulin and statins. Cancer Res., 2014, 74(19_Supplement)(Suppl.), 2173-2173. doi: 10.1158/1538-7445.AM2014-2173
  17. Wu, B.U.; Chang, J.; Jeon, C.Y.; Pandol, S.J.; Huang, B.; Ngor, E.W.; Difronzo, A.L.; Cooper, R.M. Impact of statin use on survival in patients undergoing resection for early-stage pancreatic cancer. Am. J. Gastroenterol., 2015, 110(8), 1233-1239. doi: 10.1038/ajg.2015.217 PMID: 26195180
  18. Lee, H.S.; Lee, S.H.; Lee, H.J.; Chung, M.J.; Park, J.Y.; Park, S.W.; Song, S.Y.; Bang, S. Statin use and its impact on survival in pancreatic cancer patients. Medicine, 2016, 95(19), e3607. doi: 10.1097/MD.0000000000003607 PMID: 27175667
  19. Hong, J.Y.; Nam, E.M.; Lee, J.; Park, J.O.; Lee, S.C.; Song, S.Y.; Choi, S.H.; Heo, J.S.; Park, S.H.; Lim, H.Y.; Kang, W.K.; Park, Y.S. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. Cancer Chemother. Pharmacol., 2014, 73(1), 125-130. doi: 10.1007/s00280-013-2328-1 PMID: 24162380
  20. Jeon, C.Y.; Pandol, S.J.; Wu, B.; Cook-Wiens, G.; Gottlieb, R.A.; Merz, N.B.; Goodman, M.T. The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: A SEER-medicare analysis. PLoS One, 2015, 10(4), e0121783. doi: 10.1371/journal.pone.0121783 PMID: 25830309
  21. Tingle, S.J.; Moir, J.A.; White, S.A. Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. World J. Gastrointest. Pathophysiol., 2015, 6(4), 235-242. doi: 10.4291/wjgp.v6.i4.235 PMID: 26600982
  22. e, J.Y.; Lu, S.E.; Lin, Y.; Graber, J.M.; Rotter, D.; Zhang, L.; Petersen, G.M.; Demissie, K.; Lu-Yao, G.; Tan, X.L. Differential and joint effects of metformin and statins on overall survival of elderly patients with pancreatic adenocarcinoma: A large population-based study. Cancer Epidemiol. Biomarkers Prev., 2017, 26(8), 1225-1232. doi: 10.1158/1055-9965.EPI-17-0227 PMID: 28619830
  23. Haukka, J.; Niskanen, L.; Auvinen, A. Risk of cause‐specific death in individuals with cancer—modifying role diabetes, statins and metformin. Int. J. Cancer, 2017, 141(12), 2437-2449. doi: 10.1002/ijc.31016 PMID: 28840596
  24. Huang, B.Z.; Chang, J.I.; Li, E.; Xiang, A.H.; Wu, B.U. Influence of statins and cholesterol on mortality among patients with pancreatic cancer. J. Natl. Cancer Inst., 2017, 109(5), djw275. doi: 10.1093/jnci/djw275 PMID: 28040693
  25. Farooqi, M.A.M.; Malhotra, N.; Mukherjee, S.D.; Sanger, S.; Dhesy-Thind, S.K.; Ellis, P.; Leong, D.P. Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials. PLoS One, 2018, 13(12), e0209486. doi: 10.1371/journal.pone.0209486 PMID: 30571754
  26. Abdel-Rahman, O. Statin treatment and outcomes of metastatic pancreatic cancer: A pooled analysis of two phase III studies. Clin. Transl. Oncol., 2019, 21(6), 810-816. doi: 10.1007/s12094-018-1992-3 PMID: 30465184
  27. Kjaergard, L.L.; Villumsen, J.; Gluud, C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann. Intern. Med., 2001, 135(11), 982-989. doi: 10.7326/0003-4819-135-11-200112040-00010 PMID: 11730399
  28. Jadad, A.R.; Moore, R.A.; Carroll, D.; Jenkinson, C.; Reynolds, D.J.M.; Gavaghan, D.J.; McQuay, H.J. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control. Clin. Trials, 1996, 17(1), 1-12. doi: 10.1016/0197-2456(95)00134-4 PMID: 8721797
  29. Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; Ottawa Hospital Research Institute: Ottawa, 2011, pp. 1-12.
  30. Kozak, M.M.; Anderson, E.M.; von Eyben, R.; Pai, J.S.; Poultsides, G.A.; Visser, B.C.; Norton, J.A.; Koong, A.C.; Chang, D.T. Statin and metformin use prolongs survival in patients with resectable pancreatic cancer. Pancreas, 2016, 45(1), 64-70. doi: 10.1097/MPA.0000000000000470 PMID: 26474429
  31. Beg, M.S.; Gupta, A.; Sher, D.; Ali, S.; Khan, S.; Gao, A.; Stewart, T.; Ahn, C.; Berry, J.; Mortensen, E.M. Impact of concurrent medication use on pancreatic cancer survival-SEER-medicare analysis. Am. J. Clin. Oncol., 2018, 41(8), 766-771. doi: 10.1097/COC.0000000000000359 PMID: 28079594
  32. Hamada, T.; Khalaf, N.; Yuan, C.; Morales-Oyarvide, V.; Babic, A.; Nowak, J.A.; Qian, Z.R.; Ng, K.; Rubinson, D.A.; Kraft, P. Prediagnosis use of statins associates with increased survival times of patients with pancreatic cancer. Clin. Gastroenterol. Hepatol., 2018, 16(8), 1300-1306. doi: 10.1016/j.cgh.2018.02.022
  33. Birmann, B.M.; Barnard, M.E.; Bertrand, K.A.; Bao, Y.; Crous-Bou, M.; Wolpin, B.M.; De Vivo, I.; Tworoger, S.S. Nurses' Health Study contributions on the epidemiology of less common cancers: Endometrial, ovarian, pancreatic, and hematologic. Am. J. Public Health, 2016, 106(9), 1608-1615. doi: 10.2105/AJPH.2016.303337 PMID: 27459458
  34. Giovannucci, E.; Ascherio, A.; Rimm, E.B.; Colditz, G.A.; Stampfer, M.J.; Willett, W.C. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann. Intern. Med., 1995, 122(5), 327-334. doi: 10.7326/0003-4819-122-5-199503010-00002 PMID: 7847643
  35. Iarrobino, N.A.; Gill, B.; Bernard, M.E.; Mishra, M.V.; Champ, C.E. Targeting tumor metabolism with statins during treatment for advanced-stage pancreatic cancer. Am. J. Clin. Oncol., 2018, 41(11), 1125-1131. doi: 10.1097/COC.0000000000000433 PMID: 29509593
  36. Madnick, D.; Handorf, E.; Ortiz, A.; Sorice, K.; Nagappan, L.; Moccia, M.; Cheema, K.; Vijayvergia, N.; Dotan, E.; Lynch, S.M. Investigating disparities: The effect of social environment on pancreatic cancer survival in metastatic patients. J. Gastrointest. Oncol., 2020, 11(4), 633-643. doi: 10.21037/jgo-20-39 PMID: 32953147
  37. Støer, N.C.; Bouche, G.; Pantziarka, P.; Sloan, E.K.; Andreassen, B.K.; Botteri, E. Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: A nationwide registry-based study in Norway. Acta Oncol., 2021, 60(9), 1146-1153. doi: 10.1080/0284186X.2021.1953136 PMID: 34338111
  38. Peltomaa, A.I.; Talala, K.; Taari, K.; Tammela, T.L.J.; Auvinen, A.; Murtola, T.J. Inverse association between statin use and cancer mortality relates to cholesterol level. Cancers, 2022, 14(12), 2920. doi: 10.3390/cancers14122920 PMID: 35740586
  39. Tamburrino, D.; Crippa, S.; Partelli, S.; Archibugi, L.; Arcidiacono, P.G.; Falconi, M.; Capurso, G. Statin use improves survival in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Dig. Liver Dis., 2020, 52(4), 392-399. doi: 10.1016/j.dld.2020.01.008 PMID: 32113888
  40. Jiang, W.; Hu, J.W.; He, X.R.; Jin, W.L.; He, X.Y. Statins: A repurposed drug to fight cancer. J. Exp. Clin. Cancer Res., 2021, 40(1), 241. doi: 10.1186/s13046-021-02041-2 PMID: 34303383
  41. Jian-Yu, E.; Graber, J.M.; Lu, S.E.; Lin, Y.; Lu-Yao, G.; Tan, X.L. Effect of metformin and statin use on survival in pancreatic cancer patients: A systematic literature review and meta-analysis. Curr. Med. Chem., 2018, 25(22), 2595-2607. doi: 10.2174/0929867324666170412145232 PMID: 28403788
  42. Wang, D.; Rodriguez, E.A.; Barkin, J.S.; Donath, E.M.; Pakravan, A.S. Statin use shows increased overall survival in patients diagnosed with pancreatic cancer. Pancreas, 2019, 48(4), e22-e23. doi: 10.1097/MPA.0000000000001276 PMID: 30973465
  43. Tilija Pun, N.; Jeong, C.H. Statin as a potential chemotherapeutic agent: Current updates as a monotherapy, combination therapy, and treatment for anti-cancer drug resistance. Pharmaceuticals, 2021, 14(5), 470. doi: 10.3390/ph14050470 PMID: 34065757
  44. Vallianou, N.; Kostantinou, A.; Kougias, M.; Kazazis, C. Statins and cancer. Anticancer. Agents Med. Chem., 2014, 14(5), 706-712. doi: 10.2174/1871520613666131129105035 PMID: 24295174
  45. Joharatnam-Hogan, N.; Alexandre, L.; Yarmolinsky, J.; Lake, B.; Capps, N.; Martin, R.M.; Ring, A.; Cafferty, F.; Langley, R.E. Statins as potential chemoprevention or therapeutic agents in cancer: A model for evaluating repurposed drugs. Curr. Oncol. Rep., 2021, 23(3), 29. doi: 10.1007/s11912-021-01023-z PMID: 33582975
  46. Haj Hussein, B.; Kasabri, V.; Al-Hiari, Y.; Arabiyat, S.; Ikhmais, B.; Alalawi, S.; Al-Qirim, T. Selected statins as dual antiproliferative-antiinflammatory compounds. Asian Pac. J. Cancer Prev., 2022, 23(12), 4047-4062. doi: 10.31557/APJCP.2022.23.12.4047 PMID: 36579985
  47. Zhang, Y.; Liang, M.; Sun, C.; Qu, G.; Shi, T.; Min, M.; Wu, Y.; Sun, Y. Statin use and risk of pancreatic cancer. Pancreas, 2019, 48(2), 142-150. doi: 10.1097/MPA.0000000000001226 PMID: 30640225
  48. Mansouri, A.; Reiner, Ž.; Ruscica, M.; Tedeschi-Reiner, E.; Radbakhsh, S.; Bagheri Ekta, M.; Sahebkar, A. Antioxidant effects of statins by modulating Nrf2 and Nrf2/HO-1 signaling in different diseases. J. Clin. Med., 2022, 11(5), 1313. doi: 10.3390/jcm11051313 PMID: 35268403
  49. Friesen, J.A.; Rodwell, V.W. The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome Biol., 2004, 5(11), 248. doi: 10.1186/gb-2004-5-11-248 PMID: 15535874
  50. Fatehi Hassanabad, A. Current perspectives on statins as potential anti-cancer therapeutics: Clinical outcomes and underlying molecular mechanisms. Transl. Lung Cancer Res., 2019, 8(5), 692-699. doi: 10.21037/tlcr.2019.09.08 PMID: 31737505

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2023